Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Karolinska Development

0.34 SEK

-1.29 %

Less than 1K followers

KDEV

NASDAQ Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-1.29 %
-60.41 %
-64.13 %
-65.25 %
-63.90 %
-67.18 %
-81.89 %
-82.42 %
-99.03 %

Karolinska Development is an investment company focused on long-term equity investments in biotechnology and pharmaceutical companies. The company's goal is to develop promising medical innovations stemming from academic research at Karolinska Institutet and other universities in the Nordic region. The company's portfolio includes companies in sectors such as biotechnology and medical technology. Karolinska Development was founded in 2003 and is headquartered in Solna, Sweden.

Read more
Market cap
92.91M SEK
Turnover
866.38K SEK
Revenue
1.84M
EBIT %
-497.83 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.2
2026

Annual report '25

30.4
2026

Interim report Q1'26

12.5
2026

General meeting '26

All
Press releases
ShowingAll content types
Regulatory press release12/2/2025, 9:23 AM

Notice of Extraordinary General Meeting in Karolinska Development AB (publ)

Karolinska Development
Press release12/1/2025, 10:25 AM

DNB Carnegie Access: Karolinska Development: Aims to strengthen its balance shee

Karolinska Development
Regulatory press release12/1/2025, 7:00 AM

Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and proposes change of company name to KDventures AB

Karolinska Development

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release11/17/2025, 8:15 AM

Karolinska Development’s portfolio company Umecrine Cognition publishes data on the benefits of early treatment with golexanolone in Parkinson’s disease

Karolinska Development
Press release11/17/2025, 7:00 AM

DNB Carnegie Access: Karolinska Development: Tough year so far, but news flow set to improve – Q3 review

Karolinska Development
Regulatory press release11/14/2025, 7:00 AM

Interim Report - January-September 2025

Karolinska Development
Press release11/4/2025, 7:45 AM

Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia

Karolinska Development
Press release11/3/2025, 10:59 AM

Karolinska Development’s portfolio company BOOST Pharma raises SEK 34 million through directed share issue to Sound Bioventures

Karolinska Development
Press release10/31/2025, 9:55 AM

Karolinska Development’s portfolio company BOOST Pharma presents positive long-term data for its cell-based treatment of Osteogenesis imperfecta

Karolinska Development
Press release10/28/2025, 1:32 PM

DNB Carnegie Access: Karolinska Development: Invests further in BOOST Pharma

Karolinska Development
Press release10/28/2025, 10:06 AM

Karolinska Development invests SEK 7.5 million to support BOOST Pharma’s continued development of BT-101 towards Phase 3

Karolinska Development
Press release10/24/2025, 6:45 AM

Karolinska Development’s portfolio company SVF Vaccines presents positive data from a preclinical study of SVF-001 in chronic hepatitis B and D

Karolinska Development
Press release10/9/2025, 5:24 PM

Karolinska Development's portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain

Karolinska Development
Press release10/3/2025, 6:30 AM

Karolinska Development’s portfolio company Dilafor receives patent in the US for tafoxiparin in priming of labor

Karolinska Development
Press release9/16/2025, 7:05 AM

Karolinska Development’s portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC01

Karolinska Development
Press release9/4/2025, 6:50 AM

Karolinska Development’s portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson’s disease model

Karolinska Development
Press release9/2/2025, 4:36 PM

DNB Carnegie Access: Karolinska Development: Highlights from DNB Carnegie’s Micro & Small Cap Day

Karolinska Development
Press release9/1/2025, 7:56 AM

DNB Carnegie Access: Karolinska Development: NAVPS decline – Q2 review

Karolinska Development
Regulatory press release8/29/2025, 6:00 AM

Interim Report - January-June 2025

Karolinska Development
Press release8/28/2025, 11:50 AM

Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue

Karolinska Development
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.